Although there are three myostatin inhibitors in clinical development in Phase 2/3 clinical trials involving individuals with SMA, only taldefgrobep specifically targets signaling through the receptor with competitive inhibition of activin A and myostatin (Figure 2). Here, MSTN is linked to proximal spinal muscular atrophy.